Lead Product(s) : Tibulizumab
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zura Submits Tibulizumab Phase 2 Protocol for Systemic Sclerosis to FDA
Details : Tibulizumab, an investigational humanized, tetravalent bispecific dual-antagonist antibody, designed to neutralize both IL-17A and BAFF, for the treatment of systemic sclerosis (SSc) in adults.
Product Name : ZB-106
Product Type : Antibody
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Tibulizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SDC-1801
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sareum Announces Approval to Initiate Phase 1 Clinical Trial of Its Lead Product SDC-1801
Details : SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.
Product Name : SDC-1801
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2023
Lead Product(s) : SDC-1801
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable